News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
CSL Limited Plans A$900 (US$815) Million Share Buyback After Net Profit Slips
August 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- SYDNEY—CSL Ltd. said its full-year net profit fell 8% and the company unveiled a 900 million Australian dollar (US$815 million) share buyback.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Asia
Australia
MORE ON THIS TOPIC
Immunology and inflammation
Novartis Unites With Relation in $1.7B Inflammatory Skin Disease Pact
December 9, 2025
·
2 min read
·
Tristan Manalac
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
December 8, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
·
2 min read
·
Tristan Manalac
Policy
New UK/EU Rules and AI Adoption Define CRO Priorities for 2026
December 3, 2025
·
4 min read
·
Jennifer Smith-Parker
